CD19 and neoplasm: The enhanced cytolytic activity and the increased serum IFN-γ and TNF-α concentration in vitro, as well as the increased serum IFN-γ concentration in vivo indicated that LSD1 shRNA co-expression improved the anti-tumor function of anti-CD19 CAR-T cells.